Skip to content
My WebMD Sign In, Sign Up

Ovarian Cancer Health Center

Font Size

Evidence of Benefit

Potential screening tests for ovarian cancer include transvaginal ultrasound (TVU) and the serum cancer antigen (CA) 125 assay. Several biomarkers with potential application to ovarian cancer screening are under development but have not yet been validated or evaluated for efficacy in early detection and mortality reduction.

Bimanual pelvic examination is a part of the routine pelvic examination. The sensitivity and specificity of the pelvic examination are not characterized, but examination generally detects advanced disease.[1,2]

Recommended Related to Ovarian Cancer

Ovarian Cancer Clinical Trials

New medications and treatments for ovarian cancer are constantly being developed. These must be shown to be safe and effective before doctors can prescribe them to patients. Through clinical trials, researchers test the effects of new drugs on a group of volunteers with ovarian cancer. Following a strict protocol and using carefully controlled conditions, researchers evaluate the investigational drugs under development and measure the ability of the new drug to treat ovarian cancer, its safety, and...

Read the Ovarian Cancer Clinical Trials article > >

The Pap test may occasionally detect malignant ovarian cells, but it is not sensitive (reported sensitivity of 10%-30%) and has not been evaluated for the early detection of ovarian cancer.[1] Another method of detection, cytologic examination of peritoneal lavage obtained by culdocentesis, is technically difficult, is uncomfortable for the patient, has low sensitivity for detecting early-stage disease, and has not been evaluated for screening.[1,3]

Ultrasonography

TVU has been proposed as a screening method for ovarian cancer because of its ability to reliably measure ovarian size and detect small masses.[4] The benefit of ultrasonography for the early detection of ovarian cancer and reduction in mortality has not been evaluated in controlled studies. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) is an ongoing randomized clinical trial evaluating the efficacy of annual TVU in combination with CA 125 tests to reduce ovarian cancer mortality.

An estimate of the false-positive rate associated with screening women aged 55 to 74 years is available from the initial four rounds of screening of women who participated in the PLCO and who were randomly assigned to be screened with TVU and serum CA 125 concentrations.[5,6] Among the 39,115 women randomly assigned to the screening arm, 34,261 were eligible for screens because they had not had a prior oophorectomy. Among these women, 89% had at least one screen during the four rounds of screening. The following TVU results were classified as abnormal (positive): "ovarian volume greater than 10 cm3; cyst volume greater than 10 cm3; any solid area or papillary projection extending into the cavity of a cystic ovarian tumor of any size; or any mixed (solid/cystic) component within a cystic ovarian tumor."[5,6] The screen positivity rates decreased slightly from 4.6% at the prevalent (baseline screen) to 2.9% at the fourth round of screening. The positive predictive value (PPV) of TVU was relatively constant over the screening rounds ranging from 0.7% to 1.1%.

Accurate estimates of sensitivity and specificity are difficult to obtain because few studies have conducted adequate follow-up to identify all cases. The U.K. Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) published results from their prevalent screen. The ultrasound screening arm had several levels of screening and possible referral strategies: an abnormal scan resulted in a repeat scan in 6 to 8 weeks, and if still abnormal, referral was made for a clinical assessment. Of 53 total cancers (screen-detected and interval cancers in the following year), 45 were screened positive by ultrasound (two abnormal scans) for a sensitivity of 84.9%. For invasive cancer, the sensitivity was 75%. Specificity of the ultrasound screening arm was calculated at 98.2%.[7]

1|2|3|4|5

WebMD Public Information from the National Cancer Institute

Last Updated: May 16, 2012
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.

Today on WebMD

what is your cancer risk
HEALTH CHECK
ovarian cancer overview slideshow
SLIDESHOW
 
cancer fighting foods
SLIDESHOW
15 Cancer Symptoms Women Ignore
FEATURE
 
Integrative Medicine Cancer Quiz
QUIZ
Lifestyle Tips for Depression Slideshow
SLIDESHOW
 
Screening Tests for Women
Slideshow
Graphic of ovaries within reproductive system
VIDEO
 
Ovarian Cancer Marker
VIDEO
Pets Improve Your Health
SLIDESHOW
 
Vitamin D
SLIDESHOW
Healthy meal with salmon
Article